$MCRB
Seres Therapeutics, Inc. Stock $mcrb

$mcrb Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024025464 Filed on March 05, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$64.00K	$126.3M
YoY Change	-100.0%	-93.44%	1672.24%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.93M	$17.23M	$89.19M
YoY Change	-33.57%	-23.08%	3.96%
% of Gross Profit
Research & Development	$21.70M	$26.85M	$145.9M
YoY Change	-50.64%	-41.92%	-15.65%
% of Gross Profit
Depreciation & Amortization	$1.559M	$1.632M	$6.243M
YoY Change	11.36%	0.31%	-5.82%
% of Gross Profit
Operating Expenses	$39.59M	$39.59M	$234.3M
YoY Change	-43.49%	-42.86%	-7.61%
Operating Profit	-$39.59M		-$108.0M
YoY Change	-43.9%		-56.19%
Interest Expense	-$3.015M	-$2.058M	-$5.875M
YoY Change	229.15%	341.63%	98.35%
% of Operating Profit
Other Income/Expense, Net	-$547.0K	$336.0K	-$5.741M
YoY Change	-9.74%	-1560.87%	56.56%
Pretax Income	-$40.13M	-$41.25M	-$113.7M
YoY Change	-43.61%	-40.04%	-54.54%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$40.13M	-$41.25M	-$113.7M
YoY Change	-43.61%	-40.04%	-54.54%
Net Earnings / Revenue		-64450.0%	-90.02%
Basic Earnings Per Share	-$0.27		-$0.89
Diluted Earnings Per Share	-$0.27	-$0.32	-$0.89
COMMON SHARES
Basic Shares Outstanding	151.0M	129.3M	128.0M
Diluted Shares Outstanding	146.1M		128.0M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$111.2M	$128.0M	$128.0M
YoY Change	4.36%	-29.43%	-29.43%
Cash & Equivalents	$111.2M	$128.0M	$128.0M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$4.606M	$9.124M	$9.124M
YoY Change	-51.7%	-32.03%	-32.03%
Inventory	$41.97M	$29.65M	$29.65M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$165.2M	$175.4M	$175.4M
YoY Change	42.3%	-9.94%	-9.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.12M	$22.46M	$132.3M
YoY Change	-21.36%	-2.3%	-1.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$41.47M	$41.35M	$50.94M
YoY Change	266.73%	295.16%	154.05%
Total Long-Term Assets	$176.1M	$183.2M	$183.2M
YoY Change	14.25%	18.94%	18.94%
TOTAL ASSETS
Total Short-Term Assets	$165.2M	$175.4M	$175.4M
Total Long-Term Assets	$176.1M	$183.2M	$183.2M
Total Assets	$341.3M	$358.6M	$358.6M
YoY Change	26.3%	2.81%	2.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.219M	$3.641M	$3.641M
YoY Change	-57.56%	-79.12%	-79.12%
Accrued Expenses	$14.97M	$23.14M	$23.14M
YoY Change	28.38%	26.39%	26.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due		$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$98.48M	$98.66M	$98.66M
YoY Change	54.31%	15.26%	15.26%
LONG-TERM LIABILITIES
Long-Term Debt	$102.0M	$101.5M	$101.5M
YoY Change	99.1%	100.72%	100.72%
Other Long-Term Liabilities	$1.678M	$1.628M	$203.3M
YoY Change	12.92%	12.9%	0.71%
Total Long-Term Liabilities	$1.678M	$1.628M	$304.8M
YoY Change	12.92%	12.9%	20.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$98.48M	$98.66M	$98.66M
Total Long-Term Liabilities	$1.678M	$1.628M	$304.8M
Total Liabilities	$401.0M	$403.5M	$403.5M
YoY Change	26.07%	19.37%	19.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.018B	-$978.2M
YoY Change	8.84%	13.15%
Common Stock	$958.6M	$933.4M
YoY Change	7.98%	6.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$59.74M	-$44.86M	-$44.86M
YoY Change
Total Liabilities & Shareholders Equity	$341.3M	$358.6M	$358.6M
YoY Change	26.3%	2.81%	2.81%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$40.13M	-$41.25M	-$113.7M
YoY Change	-43.61%	-40.04%	-54.54%
Depreciation, Depletion And Amortization	$1.559M	$1.632M	$6.243M
YoY Change	11.36%	0.31%	-5.82%
Cash From Operating Activities	-$35.24M	-$47.50M	-$117.4M
YoY Change	-53.99%	-10.2%	-48.71%
INVESTING ACTIVITIES
Capital Expenditures	$62.00K	$877.0K	$7.975M
YoY Change	-98.48%	-74.66%	-18.8%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$43.00K	$18.56M
YoY Change	-100.0%	-100.46%	-79.88%
Cash From Investing Activities	-$62.00K	-$877.0K	$10.58M
YoY Change	-102.26%	-114.8%	-87.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	18.76M	6.429M	71.71M
YoY Change	231.72%	39.85%	-44.67%
NET CHANGE
Cash From Operating Activities	-35.24M	-47.50M	-117.4M
Cash From Investing Activities	-62.00K	-877.0K	10.58M
Cash From Financing Activities	18.76M	6.429M	71.71M
Net Change In Cash	-16.54M	-41.95M	-35.07M
YoY Change	-75.75%	-1.0%	108.91%
FREE CASH FLOW
Cash From Operating Activities	-$35.24M	-$47.50M	-$117.4M
Capital Expenditures	$62.00K	$877.0K	$7.975M
Free Cash Flow	-$35.30M	-$48.38M	-$125.3M
YoY Change	-56.23%	-14.16%	-47.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001609809
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001609809
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2023	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2022	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2022	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2022Q4	mcrb	Fair Value Assets Level3 To Level1 Transfers Amount FairValueAssetsLevel3ToLevel1TransfersAmount	0
CY2022Q4	mcrb	Fair Value Assets Level2 To Level3 Transfers Amount FairValueAssetsLevel2ToLevel3TransfersAmount	0
CY2022Q4	mcrb	Fair Value Assets Level3 To Level2 Transfers Amount FairValueAssetsLevel3ToLevel2TransfersAmount	0
CY2022Q4	mcrb	Fair Values Assets Level2 To Level1 Transfer Amount1 FairValuesAssetsLevel2ToLevel1TransferAmount1	0
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#WarrantMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37465
CY2023	dei	Entity Registrant Name EntityRegistrantName	Seres Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4326290
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	101 Cambridgepark Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02140
CY2023	dei	Local Phone Number LocalPhoneNumber	945-9626
CY2023	dei	Trading Symbol TradingSymbol	MCRB
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127965000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163030000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	18311000
CY2023Q4	mcrb	Collaboration Receivable Related Party CollaborationReceivableRelatedParty	8674000
CY2022Q4	mcrb	Collaboration Receivable Related Party CollaborationReceivableRelatedParty	0
CY2023Q4	us-gaap	Inventory Net InventoryNet	29647000
CY2022Q4	us-gaap	Inventory Net InventoryNet	0
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9124000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13423000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	175410000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	194764000
CY2022Q4	mcrb	Fair Value Assets Level3 To Level1 Transfers Amount FairValueAssetsLevel3ToLevel1TransfersAmount	0
CY2022Q4	mcrb	Fair Value Assets Level2 To Level3 Transfers Amount FairValueAssetsLevel2ToLevel3TransfersAmount	0
CY2022Q4	mcrb	Fair Value Assets Level3 To Level2 Transfers Amount FairValueAssetsLevel3ToLevel2TransfersAmount	0
CY2022Q4	mcrb	Fair Values Assets Level2 To Level1 Transfer Amount1 FairValuesAssetsLevel2ToLevel1TransferAmount1	0
CY2023Q4	us-gaap	Investment Type Extensible Enumeration InvestmentTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#WarrantMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37465
CY2023	dei	Entity Registrant Name EntityRegistrantName	Seres Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4326290
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	101 Cambridgepark Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02140
CY2023	dei	City Area Code CityAreaCode	617
CY2023	dei	Local Phone Number LocalPhoneNumber	945-9626
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	MCRB
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	463030964
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	151009462
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127965000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163030000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	18311000
CY2023Q4	mcrb	Collaboration Receivable Related Party CollaborationReceivableRelatedParty	8674000
CY2022Q4	mcrb	Collaboration Receivable Related Party CollaborationReceivableRelatedParty	0
CY2023Q4	us-gaap	Inventory Net InventoryNet	29647000
CY2022Q4	us-gaap	Inventory Net InventoryNet	0
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9124000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13423000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	175410000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	194764000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22457000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22985000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	109793000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	110984000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	41354000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10465000
CY2023Q4	us-gaap	Assets Assets	358600000
CY2022Q4	us-gaap	Assets Assets	348784000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3641000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17440000
CY2023Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	80611000
CY2022Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	59840000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6677000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3601000
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	456000
CY2023Q4	us-gaap	Deferred Income DeferredIncome	7730000
CY2022Q4	us-gaap	Deferred Income DeferredIncome	0
CY2023Q4	mcrb	Contract With Customer Liability Current Related Party ContractWithCustomerLiabilityCurrentRelatedParty	0
CY2022Q4	mcrb	Contract With Customer Liability Current Related Party ContractWithCustomerLiabilityCurrentRelatedParty	4259000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	98659000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85596000
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	101544000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	50591000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	107942000
CY2023Q4	mcrb	Contract With Customer Liability Noncurrent Related Party ContractWithCustomerLiabilityNoncurrentRelatedParty	95364000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1442000
CY2023Q4	us-gaap	Liabilities Liabilities	403456000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22457000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22985000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	109793000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	110984000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	41354000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10465000
CY2023Q4	us-gaap	Assets Assets	358600000
CY2022Q4	us-gaap	Assets Assets	348784000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3641000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17440000
CY2023Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	80611000
CY2022Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	59840000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6677000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3601000
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	456000
CY2023Q4	us-gaap	Deferred Income DeferredIncome	7730000
CY2022Q4	us-gaap	Deferred Income DeferredIncome	0
CY2023Q4	mcrb	Contract With Customer Liability Current Related Party ContractWithCustomerLiabilityCurrentRelatedParty	0
CY2022Q4	mcrb	Contract With Customer Liability Current Related Party ContractWithCustomerLiabilityCurrentRelatedParty	4259000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	98659000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	50591000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	105715000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	107942000
CY2023Q4	mcrb	Contract With Customer Liability Noncurrent Related Party ContractWithCustomerLiabilityNoncurrentRelatedParty	95364000
CY2022Q4	mcrb	Contract With Customer Liability Noncurrent Related Party ContractWithCustomerLiabilityNoncurrentRelatedParty	92430000
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	546000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1628000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1442000
CY2023Q4	us-gaap	Liabilities Liabilities	403456000
CY2022Q4	us-gaap	Liabilities Liabilities	338001000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Liabilities Liabilities	338001000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135041467
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135041467
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125222273
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	135000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	125000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	933244000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	875181000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-978235000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-864511000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-44856000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10783000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	358600000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	348784000
CY2023	mcrb	Collaboration Revenue From Related Party CollaborationRevenueFromRelatedParty	126325000
CY2022	mcrb	Collaboration Revenue From Related Party CollaborationRevenueFromRelatedParty	7128000
CY2021	mcrb	Collaboration Revenue From Related Party CollaborationRevenueFromRelatedParty	143857000
CY2023	mcrb	Revenue From Grant RevenueFromGrant	0
CY2023	us-gaap	Revenues Revenues	126325000
CY2022	us-gaap	Revenues Revenues	7128000
CY2021	us-gaap	Revenues Revenues	144927000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	145860000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	172920000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	141891000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	87744000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	79694000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	69261000
CY2023	mcrb	Profit Loss From Research Agreements Related Party ProfitLossFromResearchAgreementsRelatedParty	704000
CY2022	mcrb	Profit Loss From Research Agreements Related Party ProfitLossFromResearchAgreementsRelatedParty	1004000
CY2023	us-gaap	Operating Expenses OperatingExpenses	234308000
CY2022	us-gaap	Operating Expenses OperatingExpenses	253618000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135041467
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135041467
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125222273
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125222273
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	135000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	125000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-978235000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-864511000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-44856000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10783000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	358600000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	348784000
CY2023	mcrb	Collaboration Revenue From Related Party CollaborationRevenueFromRelatedParty	126325000
CY2022	mcrb	Collaboration Revenue From Related Party CollaborationRevenueFromRelatedParty	7128000
CY2021	mcrb	Collaboration Revenue From Related Party CollaborationRevenueFromRelatedParty	143857000
CY2023	mcrb	Revenue From Grant RevenueFromGrant	0
CY2022	mcrb	Revenue From Grant RevenueFromGrant	0
CY2021	mcrb	Revenue From Grant RevenueFromGrant	1070000
CY2023	us-gaap	Revenues Revenues	126325000
CY2022	us-gaap	Revenues Revenues	7128000
CY2021	us-gaap	Revenues Revenues	144927000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	145860000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	172920000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	141891000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	87744000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	79694000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	69261000
CY2023	mcrb	Profit Loss From Research Agreements Related Party ProfitLossFromResearchAgreementsRelatedParty	704000
CY2022	mcrb	Profit Loss From Research Agreements Related Party ProfitLossFromResearchAgreementsRelatedParty	1004000
CY2021	mcrb	Profit Loss From Research Agreements Related Party ProfitLossFromResearchAgreementsRelatedParty	-1732000
CY2023	us-gaap	Operating Expenses OperatingExpenses	234308000
CY2022	us-gaap	Operating Expenses OperatingExpenses	253618000
CY2021	us-gaap	Operating Expenses OperatingExpenses	209420000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-107983000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-246490000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-64493000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	7301000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	3058000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	2870000
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	13176000
CY2021	us-gaap	Operating Expenses OperatingExpenses	209420000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-107983000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-246490000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-64493000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	7301000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	3058000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	2870000
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	13176000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	2910000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-705000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1045000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5741000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3667000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1085000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-250157000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65578000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.31
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.31
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128003294
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128003294
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108077043
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108077043
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91702866
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91702866
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	49000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	48000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-13000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-113712000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-250109000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65591000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	174750000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1299000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	6020000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	2910000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	134000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-705000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1045000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5741000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3667000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1085000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-250157000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65578000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.31
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.31
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128003294
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128003294
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108077043
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108077043
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91702866
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91702866
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	49000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	48000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-13000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-113712000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-250109000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65591000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	174750000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1299000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	827000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20222000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-13000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65578000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	131507000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	966000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	827000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20222000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-13000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65578000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	131507000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	966000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1769000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3279000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	96721000
CY2022	mcrb	Stock Issued During Period Value At Market Equity Offerings StockIssuedDuringPeriodValueAtMarketEquityOfferings	4447000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25482000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	48000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-250157000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10783000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	877000
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	0
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2151000
CY2023	mcrb	Stock Issued During Period Value At Market Equity Offerings StockIssuedDuringPeriodValueAtMarketEquityOfferings	18159000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2785000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34101000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	12000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-44856000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-250157000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65578000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	34101000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	25482000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	20222000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6243000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6629000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5947000
CY2023	mcrb	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	8871000
CY2022	mcrb	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	5224000
CY2021	mcrb	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	3275000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	236000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-688000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-498000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1139000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	705000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1625000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1554000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1769000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3279000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	96721000
CY2022	mcrb	Stock Issued During Period Value At Market Equity Offerings StockIssuedDuringPeriodValueAtMarketEquityOfferings	4447000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25482000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	48000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-250157000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10783000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	877000
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	0
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2151000
CY2023	mcrb	Stock Issued During Period Value At Market Equity Offerings StockIssuedDuringPeriodValueAtMarketEquityOfferings	18159000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2785000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34101000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	12000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-44856000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-250157000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65578000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	34101000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	25482000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	20222000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6243000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6629000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5947000
CY2023	mcrb	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	8871000
CY2022	mcrb	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	5224000
CY2021	mcrb	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	3275000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	236000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-688000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-498000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1139000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	705000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2526000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1625000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1554000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2023	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	-5158000
CY2022	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	-1004000
CY2021	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	1732000
CY2023	mcrb	Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets	-29124000
CY2022	mcrb	Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets	-12599000
CY2023	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	-5158000
CY2022	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	-1004000
CY2021	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	1732000
CY2023	mcrb	Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets	-29124000
CY2022	mcrb	Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets	-12599000
CY2021	mcrb	Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets	-12337000
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	8674000
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	29647000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9387000
CY2023	mcrb	Increase Decrease In Defered Income Related Party IncreaseDecreaseInDeferedIncomeRelatedParty	7730000
CY2022	mcrb	Increase Decrease In Defered Income Related Party IncreaseDecreaseInDeferedIncomeRelatedParty	0
CY2021	mcrb	Increase Decrease In Defered Income Related Party IncreaseDecreaseInDeferedIncomeRelatedParty	0
CY2023	mcrb	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-1325000
CY2022	mcrb	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-7128000
CY2021	mcrb	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-4357000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11578000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2203000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9362000
CY2023	mcrb	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2197000
CY2022	mcrb	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-4203000
CY2021	mcrb	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3550000
CY2023	mcrb	Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities	15838000
CY2022	mcrb	Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities	3336000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-228816000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6688000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7975000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9821000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9566000
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4426000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	48221000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	95971000
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	22983000
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	140470000
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	169625000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10582000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	82428000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	64088000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	96721000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021	mcrb	Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets	-12337000
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	8674000
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	29647000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9387000
CY2023	mcrb	Increase Decrease In Defered Income Related Party IncreaseDecreaseInDeferedIncomeRelatedParty	7730000
CY2022	mcrb	Increase Decrease In Defered Income Related Party IncreaseDecreaseInDeferedIncomeRelatedParty	0
CY2021	mcrb	Increase Decrease In Defered Income Related Party IncreaseDecreaseInDeferedIncomeRelatedParty	0
CY2023	mcrb	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-1325000
CY2022	mcrb	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-7128000
CY2021	mcrb	Increase Decrease In Contract With Customer Liability Related Party IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty	-4357000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11578000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2203000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9362000
CY2023	mcrb	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2197000
CY2022	mcrb	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-4203000
CY2021	mcrb	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3550000
CY2023	mcrb	Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities	15838000
CY2022	mcrb	Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities	3336000
CY2021	mcrb	Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities	43025000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117354000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-228816000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6688000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7975000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9821000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9566000
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4426000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	48221000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	95971000
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	22983000
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	140470000
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	169625000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10582000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	96721000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2023	mcrb	Proceeds From Issuance Of Common Stock From At The Market Equity Offering ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering	18159000
CY2022	mcrb	Proceeds From Issuance Of Common Stock From At The Market Equity Offering ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering	4447000
CY2021	mcrb	Proceeds From Issuance Of Common Stock From At The Market Equity Offering ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering	0
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	877000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	966000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1299000
CY2023	mcrb	Proceeds From Issuance Of Common Stock From At The Market Equity Offering ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering	18159000
CY2022	mcrb	Proceeds From Issuance Of Common Stock From At The Market Equity Offering ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering	4447000
CY2021	mcrb	Proceeds From Issuance Of Common Stock From At The Market Equity Offering ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering	0
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	877000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	966000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1299000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2151000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1769000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	827000
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	103378000
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	27606000
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	52860000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1907000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	948000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	71705000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	129602000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1178000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-35067000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16786000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	71954000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171215000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	188002000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116049000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136150000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171215000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	188002000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	12547000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	4926000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2446000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2276000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	874000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3046000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	91412000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12442000
CY2023	mcrb	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	4634000
CY2022	mcrb	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	6822000
CY2021	mcrb	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	0
CY2023	mcrb	Non Financial Liabilities For Warrants Recognised NonFinancialLiabilitiesForWarrantsRecognised	2100000
CY2022	mcrb	Non Financial Liabilities For Warrants Recognised NonFinancialLiabilitiesForWarrantsRecognised	0
CY2021	mcrb	Non Financial Liabilities For Warrants Recognised NonFinancialLiabilitiesForWarrantsRecognised	0
CY2023	mcrb	Warrants Issued Related To Term Loan And Recorded As Debt Discount WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount	2785000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2151000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1769000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	827000
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	103378000
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	27606000
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	52860000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1907000
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	948000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	71705000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	129602000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1178000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-35067000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16786000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	71954000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171215000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	188002000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116049000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136150000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171215000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	188002000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	12547000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	4926000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2446000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2276000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	874000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3046000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	91412000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12442000
CY2023	mcrb	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	4634000
CY2022	mcrb	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	6822000
CY2021	mcrb	Prepaid Rent Reclassified To Right Of Use Assets PrepaidRentReclassifiedToRightOfUseAssets	0
CY2023	mcrb	Non Financial Liabilities For Warrants Recognised NonFinancialLiabilitiesForWarrantsRecognised	2100000
CY2022	mcrb	Non Financial Liabilities For Warrants Recognised NonFinancialLiabilitiesForWarrantsRecognised	0
CY2021	mcrb	Non Financial Liabilities For Warrants Recognised NonFinancialLiabilitiesForWarrantsRecognised	0
CY2023	mcrb	Warrants Issued Related To Term Loan And Recorded As Debt Discount WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount	2785000
CY2022	mcrb	Warrants Issued Related To Term Loan And Recorded As Debt Discount WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount	0
CY2021	mcrb	Warrants Issued Related To Term Loan And Recorded As Debt Discount WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount	0
CY2023	mcrb	Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts	-6717000
CY2022	mcrb	Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts	3087000
CY2021	mcrb	Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts	31683000
CY2022	mcrb	Warrants Issued Related To Term Loan And Recorded As Debt Discount WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount	0
CY2021	mcrb	Warrants Issued Related To Term Loan And Recorded As Debt Discount WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount	0
CY2023	mcrb	Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts	-6717000
CY2022	mcrb	Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts	3087000
CY2021	mcrb	Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts	31683000
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	mcrb	Entity Incorporation Month And Year Of Incorporation EntityIncorporationMonthAndYearOfIncorporation	2010-10
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.41
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	160
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-978235000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127965000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117354000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In these consolidated financial statements, the Company uses estimates and assumptions related to revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</span></p>
CY2023	mcrb	Cash Equivalents Original Maturity Maximum Period CashEquivalentsOriginalMaturityMaximumPeriod	P90D
CY2023	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2022	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2021	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	mcrb	Entity Incorporation Month And Year Of Incorporation EntityIncorporationMonthAndYearOfIncorporation	2010-10
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.41
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	160
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-978235000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127965000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117354000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In these consolidated financial statements, the Company uses estimates and assumptions related to revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</span></p>
CY2023	mcrb	Cash Equivalents Original Maturity Maximum Period CashEquivalentsOriginalMaturityMaximumPeriod	P90D
CY2023	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2022	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2021	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127965000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163030000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136150000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171215000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. The Company has all cash, cash equivalents and investments balances at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p>
CY2023Q4	mcrb	Fair Value Assets Level1 To Level3 Transfers Amount FairValueAssetsLevel1ToLevel3TransfersAmount	0
CY2023Q4	mcrb	Fair Value Assets Level3 To Level1 Transfers Amount FairValueAssetsLevel3ToLevel1TransfersAmount	0
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127965000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163030000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8185000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	136150000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171215000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. The Company has all cash, cash equivalents and investments balances at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p>
CY2023Q4	mcrb	Fair Value Assets Level2 To Level3 Transfers Amount FairValueAssetsLevel2ToLevel3TransfersAmount	0
CY2023Q4	mcrb	Fair Value Assets Level3 To Level2 Transfers Amount FairValueAssetsLevel3ToLevel2TransfersAmount	0
CY2022Q4	mcrb	Fair Values Assets Level1 To Level2 Transfer Amount1 FairValuesAssetsLevel1ToLevel2TransferAmount1	0
CY2022Q4	mcrb	Fair Value Assets Level1 To Level3 Transfers Amount FairValueAssetsLevel1ToLevel3TransfersAmount	0
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	mcrb	Revenue Recognized Related To Sales Based Royalties RevenueRecognizedRelatedToSalesBasedRoyalties	0
CY2023	mcrb	Minimum Percentage Of Likelihood Of Tax Benefit Being Realized Upon Settlement MinimumPercentageOfLikelihoodOfTaxBenefitBeingRealizedUponSettlement	0.50
CY2023Q4	mcrb	Fair Value Assets Level3 To Level2 Transfers Amount FairValueAssetsLevel3ToLevel2TransfersAmount	0
CY2022Q4	mcrb	Fair Values Assets Level1 To Level2 Transfer Amount1 FairValuesAssetsLevel1ToLevel2TransferAmount1	0
CY2022Q4	mcrb	Fair Value Assets Level1 To Level3 Transfers Amount FairValueAssetsLevel1ToLevel3TransfersAmount	0
CY2023	mcrb	Revenue Recognized Related To Sales Based Royalties RevenueRecognizedRelatedToSalesBasedRoyalties	0
CY2023	mcrb	Minimum Percentage Of Likelihood Of Tax Benefit Being Realized Upon Settlement MinimumPercentageOfLikelihoodOfTaxBenefitBeingRealizedUponSettlement	0.50
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14709000
CY2023Q4	mcrb	Collaboration Payable Related Party CollaborationPayableRelatedParty	28053000
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	0
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2023Q4	mcrb	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2023Q4	mcrb	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	0
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2023Q4	mcrb	Fair Value Assets Level1 To Level2 Transfers Amount1 FairValueAssetsLevel1ToLevel2TransfersAmount1	0
CY2023Q4	mcrb	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2023Q4	mcrb	Fair Value Assets Level1 To Level3 Transfers Amount FairValueAssetsLevel1ToLevel3TransfersAmount	0
CY2023Q4	mcrb	Fair Value Assets Level3 To Level1 Transfers Amount FairValueAssetsLevel3ToLevel1TransfersAmount	0
CY2023Q4	mcrb	Fair Value Assets Level2 To Level3 Transfers Amount FairValueAssetsLevel2ToLevel3TransfersAmount	0
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	18321000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	18311000
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2023	mcrb	Cash Equivalents Original Maturity Maximum Period CashEquivalentsOriginalMaturityMaximumPeriod	P90D
CY2022	mcrb	Cash Equivalents Original Maturity Maximum Period CashEquivalentsOriginalMaturityMaximumPeriod	P90D
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4426000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	25221000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0
CY2023Q4	us-gaap	Inventory Net InventoryNet	29647000
CY2022Q4	us-gaap	Inventory Net InventoryNet	0
CY2022Q4	us-gaap	Inventory Net InventoryNet	0
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	26794000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14709000
CY2023Q4	mcrb	Collaboration Payable Related Party CollaborationPayableRelatedParty	28053000
CY2022Q4	mcrb	Collaboration Payable Related Party CollaborationPayableRelatedParty	34770000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2772000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3644000
CY2023Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	80611000
CY2022Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	59840000
CY2022Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	18321000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	18311000
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1401000
CY2023	mcrb	Cash Equivalents Original Maturity Maximum Period CashEquivalentsOriginalMaturityMaximumPeriod	P90D
CY2022	mcrb	Cash Equivalents Original Maturity Maximum Period CashEquivalentsOriginalMaturityMaximumPeriod	P90D
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4426000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	25221000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0
CY2023Q4	us-gaap	Inventory Net InventoryNet	29647000
CY2022Q4	us-gaap	Inventory Net InventoryNet	0
CY2022Q4	us-gaap	Inventory Net InventoryNet	0
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	26794000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2022Q4	mcrb	Collaboration Payable Related Party CollaborationPayableRelatedParty	34770000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2772000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3644000
CY2023Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	80611000
CY2022Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	59840000
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	Certain leases include one or more options to renew, exercisable at the Company’s sole discretion, with renewal terms that can extend the lease from approximately one year to ten years.
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	73595000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	68025000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51138000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45040000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22457000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22985000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6243000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6629000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5947000
CY2023	mcrb	Disposal Of Fully Depreciated Assets Cost Basis DisposalOfFullyDepreciatedAssetsCostBasis	145000
CY2022	mcrb	Disposal Of Fully Depreciated Assets Cost Basis DisposalOfFullyDepreciatedAssetsCostBasis	1857000
CY2023Q4	mcrb	Accrued Clinical And Development Costs Current AccruedClinicalAndDevelopmentCostsCurrent	1404000
CY2022Q4	mcrb	Accrued Clinical And Development Costs Current AccruedClinicalAndDevelopmentCostsCurrent	6717000
CY2023Q4	mcrb	Manufacturing And Quality Costs ManufacturingAndQualityCosts	31917000
CY2022Q4	mcrb	Manufacturing And Quality Costs ManufacturingAndQualityCosts	0
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16465000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	73595000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	68025000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51138000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45040000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22457000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22985000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6243000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6629000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5947000
CY2023	mcrb	Disposal Of Fully Depreciated Assets Cost Basis DisposalOfFullyDepreciatedAssetsCostBasis	145000
CY2022	mcrb	Disposal Of Fully Depreciated Assets Cost Basis DisposalOfFullyDepreciatedAssetsCostBasis	1857000
CY2023Q4	mcrb	Accrued Clinical And Development Costs Current AccruedClinicalAndDevelopmentCostsCurrent	1404000
CY2022Q4	mcrb	Accrued Clinical And Development Costs Current AccruedClinicalAndDevelopmentCostsCurrent	6717000
CY2023Q4	mcrb	Manufacturing And Quality Costs ManufacturingAndQualityCosts	31917000
CY2022Q4	mcrb	Manufacturing And Quality Costs ManufacturingAndQualityCosts	0
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16465000
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	Certain leases include one or more options to renew, exercisable at the Company’s sole discretion, with renewal terms that can extend the lease from approximately one year to ten years.
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2022Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2022Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	452000
CY2023	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	10400000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	109793000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	110984000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6677000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3601000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	105715000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	107942000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	112392000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	111543000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	22324000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8830000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5170000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1477000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1375000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1452000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	7229000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	4547000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	3300000
CY2023	mcrb	Sublease Income1 SubleaseIncome1	0
CY2022	mcrb	Sublease Income1 SubleaseIncome1	0
CY2021	mcrb	Sublease Income1 SubleaseIncome1	-1575000
CY2023	us-gaap	Lease Cost LeaseCost	31030000
CY2022Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	452000
CY2023	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	10400000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	109793000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	110984000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6677000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3601000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	105715000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	107942000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	112392000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	111543000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	22324000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8830000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5170000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1477000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1375000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1452000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	7229000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	4547000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	3300000
CY2023	mcrb	Sublease Income1 SubleaseIncome1	0
CY2022	mcrb	Sublease Income1 SubleaseIncome1	0
CY2021	mcrb	Sublease Income1 SubleaseIncome1	-1575000
CY2023	us-gaap	Lease Cost LeaseCost	31030000
CY2022	us-gaap	Lease Cost LeaseCost	14752000
CY2021	us-gaap	Lease Cost LeaseCost	8347000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	15656000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	7809000
CY2022	us-gaap	Lease Cost LeaseCost	14752000
CY2021	us-gaap	Lease Cost LeaseCost	8347000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	15656000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	7809000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6821000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19869000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	22062000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	22674000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	23347000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	23580000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	65819000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	177351000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	64959000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	112392000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y11M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y11M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13
CY2023Q2	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	50446000
CY2023Q2	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	30
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	24750000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	33000000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	33000000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	19250000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	110000000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	200000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	341974000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6821000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19869000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	22062000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	22674000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	23347000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	23580000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	65819000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	177351000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	64959000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	112392000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y11M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y11M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13
CY2023Q2	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	50446000
CY2023Q2	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	30
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	24750000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	33000000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	33000000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	19250000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	110000000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	27452000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	29922000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3540000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4044000
CY2023Q4	mcrb	Deferred Tax Assets Section163 J Limitation Cares Act DeferredTaxAssetsSection163JLimitationCARESAct	3741000
CY2022Q4	mcrb	Deferred Tax Assets Section163 J Limitation Cares Act DeferredTaxAssetsSection163JLimitationCARESAct	2303000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	398000
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8738243
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14940034
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.03
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11608000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2508553
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.44
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	260640
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.36
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2343835
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.3
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14844112
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.64
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M15D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	14844112
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.64
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M28D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10488694
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.09
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y7M9D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.51
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.53
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.33
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	438000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	981000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4727000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	27452000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	29922000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3540000
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8738243
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14940034
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.03
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11608000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2508553
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.44
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	260640
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.36
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2343835
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.3
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14844112
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.64
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M15D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	14844112
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.64
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M28D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10488694
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.09
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y7M9D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.51
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.53
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.33
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	438000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	981000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4727000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4044000
CY2023Q4	mcrb	Deferred Tax Assets Section163 J Limitation Cares Act DeferredTaxAssetsSection163JLimitationCARESAct	3741000
CY2022Q4	mcrb	Deferred Tax Assets Section163 J Limitation Cares Act DeferredTaxAssetsSection163JLimitationCARESAct	2303000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34101000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25482000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20222000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	35036000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-250157000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65578000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128003294
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128003294
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108077043
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108077043
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91702866
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91702866
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.31
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.31
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2023Q4	mcrb	Workforce Reduction Rate WorkforceReductionRate	0.41
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	160
CY2023	us-gaap	Restructuring Charges RestructuringCharges	5606000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	398000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	396000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	169000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34101000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25482000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20222000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	35036000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-113724000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-250157000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-65578000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128003294
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108077043
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108077043
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91702866
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91702866
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.31
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.31
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2023Q4	mcrb	Workforce Reduction Rate WorkforceReductionRate	0.41
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	160
CY2023	us-gaap	Restructuring Charges RestructuringCharges	5606000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	396000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	169000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	200000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	341974000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	5606000
CY2016Q1	mcrb	Collaborative Arrangement Upfront License Fee Received CollaborativeArrangementUpfrontLicenseFeeReceived	120000000
CY2023	mcrb	Contract With Customer Liability Revenue Recognized With Related Party ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty	1325000
CY2022	mcrb	Contract With Customer Liability Revenue Recognized With Related Party ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty	7128000
CY2023	mcrb	Share Of Related Party Net Loss ShareOfRelatedPartyNetLoss	-18873000
CY2022	mcrb	Share Of Related Party Net Loss ShareOfRelatedPartyNetLoss	0
CY2021	mcrb	Share Of Related Party Net Loss ShareOfRelatedPartyNetLoss	0
CY2023	mcrb	Profit On Transfer Of Related Party Inventory ProfitOnTransferOfRelatedPartyInventory	23327000
CY2022	mcrb	Profit On Transfer Of Related Party Inventory ProfitOnTransferOfRelatedPartyInventory	0
CY2022	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	-1004000
CY2021	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	1732000
CY2023	mcrb	Profit Loss From Research Agreement Related Party ProfitLossFromResearchAgreementRelatedParty	-704000
CY2022	mcrb	Profit Loss From Research Agreement Related Party ProfitLossFromResearchAgreementRelatedParty	-1004000
CY2021	mcrb	Profit Loss From Research Agreement Related Party ProfitLossFromResearchAgreementRelatedParty	1732000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Restructuring Charges RestructuringCharges	5606000
CY2016Q1	mcrb	Collaborative Arrangement Upfront License Fee Received CollaborativeArrangementUpfrontLicenseFeeReceived	120000000
CY2023	mcrb	Contract With Customer Liability Revenue Recognized With Related Party ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty	1325000
CY2022	mcrb	Contract With Customer Liability Revenue Recognized With Related Party ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty	7128000
CY2023	mcrb	Share Of Related Party Net Loss ShareOfRelatedPartyNetLoss	-18873000
CY2022	mcrb	Share Of Related Party Net Loss ShareOfRelatedPartyNetLoss	0
CY2021	mcrb	Share Of Related Party Net Loss ShareOfRelatedPartyNetLoss	0
CY2023	mcrb	Profit On Transfer Of Related Party Inventory ProfitOnTransferOfRelatedPartyInventory	23327000
CY2022	mcrb	Profit On Transfer Of Related Party Inventory ProfitOnTransferOfRelatedPartyInventory	0
CY2021	mcrb	Profit On Transfer Of Related Party Inventory ProfitOnTransferOfRelatedPartyInventory	0
CY2023	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	-5158000
CY2022	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	-1004000
CY2021	mcrb	Collaboration Profit Loss Related To Pre Launch Activities CollaborationProfitLossRelatedToPreLaunchActivities	1732000
CY2023	mcrb	Profit Loss From Research Agreement Related Party ProfitLossFromResearchAgreementRelatedParty	-704000
CY2022	mcrb	Profit Loss From Research Agreement Related Party ProfitLossFromResearchAgreementRelatedParty	-1004000
CY2021	mcrb	Profit Loss From Research Agreement Related Party ProfitLossFromResearchAgreementRelatedParty	1732000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.043
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.031
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.166
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.078
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.028
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.014
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.004
CY2023	mcrb	Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves	0.008
CY2022	mcrb	Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves	0.046
CY2021	mcrb	Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.004
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.312
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.229
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.404
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	142506000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	132560000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	52843000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	48854000
CY2023Q4	mcrb	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	55572000
CY2022Q4	mcrb	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	38894000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	25898000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	20048000
CY2023Q4	mcrb	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	29855000
CY2022Q4	mcrb	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	29717000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.043
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.031
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.166
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.078
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.028
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.014
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.004
CY2023	mcrb	Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves	0.008
CY2022	mcrb	Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves	0.046
CY2021	mcrb	Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.004
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.312
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.229
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.404
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	142506000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	132560000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	52843000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	48854000
CY2023Q4	mcrb	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	55572000
CY2022Q4	mcrb	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	38894000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	25898000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	20048000
CY2023Q4	mcrb	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	29855000
CY2022Q4	mcrb	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	29717000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	306938000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2023Q4	mcrb	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	29165000
CY2022Q4	mcrb	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	29568000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	29165000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	29568000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	312809000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	277370000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	102558000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	160586000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	277370000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	220114000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	193736000
CY2023	mcrb	Increase In Valuation Allowance Deferred Tax Asset IncreaseInValuationAllowanceDeferredTaxAsset	35439000
CY2022	mcrb	Increase In Valuation Allowance Deferred Tax Asset IncreaseInValuationAllowanceDeferredTaxAsset	57256000
CY2021	mcrb	Increase In Valuation Allowance Deferred Tax Asset IncreaseInValuationAllowanceDeferredTaxAsset	26378000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	312809000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	277370000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	220114000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12528000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1001000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	12528000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	306938000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2023Q4	mcrb	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	29165000
CY2022Q4	mcrb	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	29568000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	29165000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	29568000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	312809000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	277370000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	102558000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	160586000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	277370000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	220114000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	193736000
CY2023	mcrb	Increase In Valuation Allowance Deferred Tax Asset IncreaseInValuationAllowanceDeferredTaxAsset	35439000
CY2022	mcrb	Increase In Valuation Allowance Deferred Tax Asset IncreaseInValuationAllowanceDeferredTaxAsset	57256000
CY2021	mcrb	Increase In Valuation Allowance Deferred Tax Asset IncreaseInValuationAllowanceDeferredTaxAsset	26378000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	312809000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	277370000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	220114000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12528000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1001000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	12528000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13529000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12528000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Deferred Income DeferredIncome	7730000
CY2022Q4	us-gaap	Deferred Income DeferredIncome	0
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8738243
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	3.15
CY2022Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27525000
CY2016Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2016Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2003000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1921000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1087000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13529000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12528000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Deferred Income DeferredIncome	7730000
CY2022Q4	us-gaap	Deferred Income DeferredIncome	0
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8738243
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	3.15
CY2022Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27525000
CY2016Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2016Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2003000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1921000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1087000

Files In Submission

Name	View Source	Status
0000950170-24-025464-index-headers.html	Edgar Link	pending
0000950170-24-025464-index.html	Edgar Link	pending
0000950170-24-025464.txt	Edgar Link	pending
0000950170-24-025464-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img233233405_0.jpg	Edgar Link	pending
img233233405_1.jpg	Edgar Link	pending
img233233405_2.jpg	Edgar Link	pending
img233233405_3.jpg	Edgar Link	pending
img233233405_4.jpg	Edgar Link	pending
mcrb-20231231.htm	Edgar Link	pending
mcrb-20231231.xsd	Edgar Link	pending
mcrb-ex10_26.htm	Edgar Link	pending
mcrb-ex10_6.htm	Edgar Link	pending
mcrb-ex23_1.htm	Edgar Link	pending
mcrb-ex31_1.htm	Edgar Link	pending
mcrb-ex31_2.htm	Edgar Link	pending
mcrb-ex32_1.htm	Edgar Link	pending
mcrb-ex32_2.htm	Edgar Link	pending
mcrb-ex4_2.htm	Edgar Link	pending
mcrb-ex97_1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
mcrb-20231231_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MCRB
Seres Therapeutics, Inc. Stock $mcrb

2024 Q1 Form 10-K Financial Statement

#000095017024025464 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MCRB Seres Therapeutics, Inc. Stock $mcrb

2024 Q1 Form 10-K Financial Statement

#000095017024025464 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MCRB
Seres Therapeutics, Inc. Stock $mcrb